Key takeaway
In 65 adults in New Zealand with overweight or obesity plus a cardiometabolic condition, a 12-week whole food plant-based programme cut BMI 3.9 kg/m2 more than normal care at 6 months (P<0.0001), but the cholesterol difference was not significant (P=0.1). Only 49 completed 6 months, and the study was not blinded to diet.
Study design
Randomised trial
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
The research question
Few randomised trials have tested a whole food plant-based diet for raised BMI or cholesterol. The authors tested whether a community programme in a general practice could lower BMI and cholesterol at 6 months, with follow-up later extended.
Who and how
Randomised controlled trial in one general practice in Gisborne, New Zealand. Adults aged 35-70 with obesity or overweight and at least one of type 2 diabetes, ischaemic heart disease, hypertension or hypercholesterolaemia were randomised (control n=32, intervention n=33). Everyone received normal care. The intervention group attended facilitated meetings twice weekly for 12 weeks and followed a non-energy-restricted whole food plant-based diet with vitamin B12 supplementation. Primary end points were BMI and cholesterol at 6 months.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Of 65 people randomised, 49 (75.4%) completed 6 months; 23 (70%) of the intervention group were followed up at 12 months.
- 2Mean BMI fell by 4.4 with the plant-based diet versus 0.4 with normal care, a difference of 3.9 kg/m2 (95% CI ±1, P<0.0001).
- 3Mean cholesterol fell by 0.71 versus 0.26 mmol/l, a difference of 0.45 mmol/l (95% CI ±0.54, P=0.1), which was not significant. Excluding dropouts, the difference was 0.56 mmol/l (95% CI ±0.54, P=0.05).
- 4At 12 months the diet group's mean reductions were 4.2 (±0.8) BMI points and 0.55 (±0.54, P=0.05) mmol/l total cholesterol. No serious harms were reported.
Limits & uncertainty
- 1Small trial from a single practice, with about a quarter of participants lost by 6 months, and at 12 months only the intervention group's follow-up is reported.
- 2Participants knew which group they were in, and the intervention bundled a diet, twice-weekly meetings and supplements, so the diet alone cannot be credited.
- 3The primary cholesterol result was not significant; the near-significant result came from a secondary analysis that excluded dropouts.
- 4The conclusion that weight loss exceeded other trials without energy limits is a comparison across studies, not a result of this trial.
What to take from it
A structured, group-supported plant-based programme was linked to a large BMI drop within 6 months in this small trial. It does not show that diet alone caused it, or that results would hold in other settings. If you have diabetes, heart disease or take medication, check with your clinician before changing your diet.
Reading your own data
Weight and BMI trends are the easiest numbers to follow, using the same scale, time of day and clothing. If you also have blood pressure or cholesterol tests, compare them over months rather than by a single reading.
How to read this evidence
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background/objective
There is little randomised evidence using a whole food plant-based (WFPB) diet as intervention for elevated body mass index (BMI) or dyslipidaemia. We investigated the effectiveness of a community-based dietary programme. Primary end points: BMI and cholesterol at 6 months (subsequently extended).
Subjects
Ages 35-70, from one general practice in Gisborne, New Zealand. Diagnosed with obesity or overweight and at least one of type 2 diabetes, ischaemic heart disease, hypertension or hypercholesterolaemia. Of 65 subjects randomised (control n=32, intervention n=33), 49 (75.4%) completed the study to 6 months. Twenty-three (70%) intervention participants were followed up at 12 months.
Methods
All participants received normal care. Intervention participants attended facilitated meetings twice-weekly for 12 weeks, and followed a non-energy-restricted WFPB diet with vitamin B_(12) supplementation.
Results
At 6 months, mean BMI reduction was greater with the WFPB diet compared with normal care (4.4 vs 0.4, difference: 3.9 kg m^(-2) (95% confidence interval (CI)±1), P<0.0001). Mean cholesterol reduction was greater with the WFPB diet, but the difference was not significant compared with normal care (0.71 vs 0.26, difference: 0.45 mmol l^(-1) (95% CI±0.54), P=0.1), unless dropouts were excluded (difference: 0.56 mmol l^(-1) (95% CI±0.54), P=0.05). Twelve-month mean reductions for the WFPB diet group were 4.2 (±0.8) kg m^(-)^(2) BMI points and 0.55 (±0.54, P=0.05) mmol l^(-1) total cholesterol. No serious harms were reported.
Conclusions
This programme led to significant improvements in BMI, cholesterol and other risk factors. To the best of our knowledge, this research has achieved greater weight loss at 6 and 12 months than any other trial that does not limit energy intake or mandate regular exercise.
Sources & attribution
The BROAD study: A randomised controlled trial using a whole food plant-based diet in the community for obesity, ischaemic heart disease or diabetes.
Wright N, Wilson L, Smith M, Duncan B, McHugh P.
Nutrition & diabetes · 2017-03-20
DOI: 10.1038/nutd.2017.3 ↗PubMed · 28319109 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

